Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Hutchmed China confident after being added to SEC list

Thu, 31st Mar 2022 10:04

(Sharecast News) - Hutchmed China updated the market on its status under the United States 'Holding Foreign Companies Accountable Act' on Thursday.

The AIM-traded firm said that, following its implementation of rules under the act, the US Securities and Exchange Commission (SEC) added Hutchmed to its list of issuers identified under the act.

It was provisionally named as an SEC-identified Issuer on 8 March, following the filing of its annual report on 3 March.

The SEC estimated that 273 registrants might be identified under the act as part of its review of registrants in 2020.

"We anticipate that other similarly-situated US-listed companies with operations in Hong Kong and other parts of China will be added once they file their annual reports with the SEC," the board said in its statement.

"As the company continues to monitor market developments and evaluate all strategic options, with the appropriate counsel and guidance, it would like to note that this update has no impact on business operations."

Hutchmed said it understood that the motivation behind the act was to ensure appropriate transparency and disclosure, so that investors would be able to make informed investment decisions.

"This we fully support and have been committed to ever since our initial listing in London in 2006.

"As always, we will continue complying with relevant laws and regulations in all the jurisdictions we are listed.

"Furthermore, we are working to maintain communication with the China Securities Regulatory Commission (CSRC) to understand if there are further updates on their discussions with the US authorities regarding how China-based companies may be able to meet the requirements of the act."

Hutchmed said it would continue to evaluate its options to remain listed in the US, including assessing the merits of appointing an auditor outside of China if and when the contribution of its international business to the group exceeded its China business.

At 1235 BST, shares in Hutchmed China were down 3.49% in London, at 290.5p.

Related Shares

More News
24 Jun 2024 12:20

Hutchmed partner gets European approval for fruqintinib

(Sharecast News) - Hutchmed China announced on Monday that its partner Takeda has received approval from the European Commission for 'Fruzaqla', or fr...

24 Jun 2024 10:00

IN BRIEF: Hutchmed China notes Takeda obtains EU approval for Fruzaqla

Hutchmed (China) Ltd - Hong Kong-headquartered biopharmaceutical company - Notes that Takeda Pharmaceuticals Co Ltd received a notification from the E...

17 Jun 2024 10:32

Hutchmed celebrates "promising" results for sovleplenib in China

(Alliance News) - Hutchmed (China) Ltd on Monday said its phase 3 trial of sovleplenib showed "consistent benefits" in adults with autoimmune disorder...

17 Jun 2024 09:28

Hutchmed publishes positive sovleplenib trial results

(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Hae...

7 Jun 2024 18:13

IN BRIEF: Hutchmed (China) begins trial of menin inhibitor HMPL-506

Hutchmed (China) Ltd - Hong Kong-headquartered biopharmaceutical company - Says that it has initiated Phase I clinical trial of its menin inhibitor HM...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.